<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441934</url>
  </required_header>
  <id_info>
    <org_study_id>ARC209</org_study_id>
    <nct_id>NCT01441934</nct_id>
  </id_info>
  <brief_title>SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD</brief_title>
  <acronym>SPHERIC-1</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Sildenafil in the Treatment of Patients With Pulmonary Hypertension Associated to Chronic Obstructive Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Association of Hospital Pneumologists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Association of Hospital Pneumologists</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although pulmonary hypertension (PH) is a quite frequent complication of advanced pulmonary
      diseases, and it is an independent prognostic factor, until now no evidence-based treatment
      approach exists for those patients.

      This study will address if the drug sildenafil can lower pulmonary vascular resistance in
      patients with significant pulmonary hypertension (high blood pressure in the lungs)
      associated to chronic obstructive pulmonary disease (COPD). It will see if this treatment can
      improve effort capacity, quality of life without causing a deterioration in pulmonary gas
      exchange (mainly arterial oxygenation).

      Patients 18 years of age and older with moderate COPD and pulmonary hypertension (mean
      pulmonary arterial pressure &gt;30 mmHg) may be eligible for this study. Participants are
      randomly assigned to receive sildenafil or placebo (pill with no drug) for 16 weeks.

      Before starting treatment (baseline), and a the end of the study, the patients have a
      comprehensive assessment including:

        -  a chest x-ray and CT scan (only at baseline);

        -  pulmonary function tests to measure how much air the patient can breathe in and out, and
           the capacity of diffusion of gases;

        -  arterial blood gases analysis (for safety reason this examination is performed at
           baseline, before the randomization after one hour from the administration of a tablet
           (20 mg) of sildenafil, and every month)

        -  an echocardiogram (heart ultrasound) (only at baseline);

        -  a 6-minute walk test to measure exercise capacity;

        -  a quality-of-life assessment (SF-36 questionnaire)

        -  a right heart catheterization to evaluate the severity of hypertension

      At the end of the 16-week period, patients may opt to continue to receive sildenafil and
      monitoring in an open-label phase of the study for up to 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary vascular resistance (PVR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>PVR are measured by right cath study as the following formula:
PVR= (mean pulmonary arterial pressure-pulmonary arterial wedge pressure)/cardiac output</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gas analysis</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - Borg scale</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The dyspnea is assessed by an analogic scale from 0 (no dyspnea) to 10 (very severe dyspnea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - Bode Index</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The BODE Index is a composite marker of disease taking into consideration the systemic nature of COPD: FEV1% pred = predicted amount as a percentage of the forced expiratory lung volume in one second; 6MWD = six minute walking distance; MMRC = modified medical research council dyspnea scale; BMI = body mass index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity - Quality of Life</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Quality of Life is assessed by a standardized questionnaire (SF-36 questionnaire) at baseline and the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity testing - 6 Minutes walking test</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The six-minute walk test is performed in a straight corridor (length 25-30 meters) in the same environmental conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil citrate</intervention_name>
    <description>sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment</description>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pills</intervention_name>
    <description>placebo t.i.d.</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affected by stable COPD under optimal treatment, chronic oxygen therapy in
             patients with hypoxia, with PaO2 at rest ≥ 60 mmHg and PaCO2≤ 55 mmHg, aged between 18
             and 80 years old:

          -  Group 1: BPCO GOLD I‐III (post bronchodilator FEV1 ≥ 30%, FEV1/FVC ≤ 0,7 , TLC ≥ 70%)
             + PAPm ≥ 30 mmHg and PCP &lt;15 mmHg

          -  Group 2: BPCO GOLD IV (post bronchodilator FEV1 &lt;30%, FEV1/FVC ≤ 0,7 , TLC ≥ 70%) +
             PAPm ≥ 35 mmHg and PCP &lt;15 mmHg

        Exclusion Criteria:

          -  Different types of pulmonary hypertension (chronic, thromboembolic pulmonary
             hypertension, pulmonary arterial hypertension etc.)

          -  Significant left cardiac disease (LVEF &lt;45%, cardiomyopathy, valvulopathy, unstable
             coronaropathy)

          -  Treatment with nitrates in the last 10 days, or in need of other nitrate therapy for
             different diseases

          -  Treatment with other specific drugs for arterial pulmonary hypertension (less than 4
             weeks)

          -  Significant systemic disease other than COPD

          -  Recent exacerbations of chronic bronchitis (&lt; 4 weeks)

          -  Pregnancy or breastfeeding, or women without an adequate contraceptive method for the
             whole study duration

          -  History of anaphylaxis or allergic reactions to 5-phosphodiesterase inhibitors

          -  Cancers within the last 5 years with the exception of localized cancers of the skin or
             of the cervix

          -  Hepatic insufficiency or chronic renal failure or hemoglobinemia &lt; 10 g/dL during the
             screening phase

          -  Contraindications to subministration as per SPC

          -  Mental disorder, alcohol abuse, chronic alcoholism, drug abuse

          -  Subjects unable to sign the informed consent form

          -  Subjects unable to walk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrizio Vitulo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Medicine - Pulmonary Medicine - IsMeTT Palermo, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmine D. Vizza, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulmonary Hypertension Center - Dept. of Cardiovascular and Respiratory Sciences - I° School of Medicine - Sapienza University of Rome (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Unit - Azienda Ospedaliera Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonary Diseases Clinic - Azienda Ospedaliera Universitaria - Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonary Clinic - Federico II University - Azienda Ospedaliera V. Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Sofia, MD</last_name>
      <email>matteo.sofia@unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoracic Surgery Clinic - Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine - Pulmonary Medicine - IsMeTT</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizio Vitulo, MD</last_name>
      <phone>00390912192111</phone>
      <email>pvitulo@ismett.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Diseases Clinic - Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiberio Oggionni, MD</last_name>
      <email>t.oggionni@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Hypertension Center - Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmime D. Vizza, MD</last_name>
      <phone>00390649979051</phone>
      <email>dario.vizza@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Pulmonary Unit - Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Rottoli, MD</last_name>
      <email>rottoli@unisi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Unit - Azienda Ospedaliera Universitaria San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10143</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Libertucci, MD</last_name>
      <email>dlibertucci@molinette.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Unit - Azienda Ospedaliera Universitaria Ospedali Riuniti di Trieste</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Confalonieri, MD</last_name>
      <email>marco.confalonieri@aots.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Mediterranean Institute for Transplantation and Advanced Specialized Therapies</investigator_affiliation>
    <investigator_full_name>Dr. Patrizio Vitulo</investigator_full_name>
    <investigator_title>Head of Pulmonary Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

